Fludarabine in patients with advanced and/or resistant B‐chronic lymphocytic leukemia
- 1 August 1993
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 51 (2) , 93-97
Abstract
Abstract: In this study, we evaluated the efficacy of fludarabine (FLU), an adenine nucleoside analogue, in 35 previously treated patients with advanced and progressed B‐cell chronic lymphocytic leukemia (B‐CLL) and in 6 at diagnosis. All patients were treated at a dose of 25 mg/m2per day for 5 consecutive days (mean number of courses was 5, with a range from 4 to 6). The majority of patients experienced a beneficial effect on hematological parameters. In particular, a remarkable reduction of lymphocyte count together with an increase of neutrophils and platelets was observed. The overall response rate was 42% with 1 complete response and 16 partial responses. Ten patients achieved minor responses and the remaining 14 showed no benefit from treatment. An increased response rate was achieved in 6 untreated patients who showed an overall response rate of 67% (4/6). The major complications observed were neutropenia (66%) and febrile episodes (44%) that were generally infection‐related and were fatal in 3 cases. Because we were dealing with patients whose disease was advanced and/or resistant to treatment, the overall results may be considered encouraging with acceptable toxic reactions not superior to those frequently observed with polychemotherapy.Keywords
This publication has 22 references indexed in Scilit:
- Response to 2-Chlorodeoxyadenosine in Patients with B-Cell Chronic Lymphocytic Leukemia Resistant to FludarabineNew England Journal of Medicine, 1992
- Treatment of advanced chronic lymphocytic leukemia by fludarabineAnnals of Hematology, 1991
- Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemiaThe American Journal of Medicine, 1991
- 2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic LeukemiaLeukemia & Lymphoma, 1991
- 2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive NucleosideLeukemia & Lymphoma, 1991
- Sustained Response of Refractory Prolymphocytic Leukemia to FludarabineActa Haematologica, 1991
- Pentostatin in Refractory Chronic Lymphocytic Leukemia: A Phase II Trial of the European Organization for Research and Treatment of CancerJNCI: Journal of the National Cancer Institute, 1990
- Activity of Fludarabine Monophosphate in Patients With Advanced Mycosis Fungoides: A Southwest Oncology Group StudyJNCI: Journal of the National Cancer Institute, 1990
- Pharmacokinetic study of fludarabine phosphate (NSC 312887)Cancer Chemotherapy and Pharmacology, 1986
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982